| Drug Name |
Asenapine |
| Drug ID |
BADD_D00172 |
| Description |
Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009. |
| Indications and Usage |
Used for treatment in psychosis, schizophrenia and schizoaffective disorders, manic disorders, and bipolar disorders as monotherapy or in combination. |
| Marketing Status |
approved |
| ATC Code |
N05AH05 |
| DrugBank ID |
DB06216
|
| KEGG ID |
D11769
|
| MeSH ID |
C522667
|
| PubChem ID |
9903970
|
| TTD Drug ID |
D00JRA
|
| NDC Product Code |
62332-198; 42794-017; 62332-199; 68968-0174; 68968-0173; 46708-198; 46708-199; 42794-016; 68968-0172; 62332-544; 46708-544 |
| UNII |
JKZ19V908O
|
| Synonyms |
asenapine | trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole | asenapine maleate | ORG 5222 | ORG-5222 | 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3-6,7)oxepino(4,5-c)pyrrole | Secuado | Saphris |
